InfuSystem (INFU) investor relations material

Executive summary

• Net revenues for Q1 2026 were $33.7 million, down 3% year-over-year, primarily due to a strategic contract restructuring with GE HealthCare.

• Adjusted EBITDA was $6.4 million, flat year-over-year, with margin improving to 18.9% from 18.2%.

• Gross profit increased 3% to $19.7 million, with gross margin up to 58.4% from 55.2% year-over-year.

• Net income reached $1.0 million, reversing a net loss of $0.3 million in Q1 2025; diluted EPS was $0.05.

• Strategic initiatives included expansion in wound care and the successful go-live of a new ERP system in March 2026.

Financial highlights

• Patient Services revenue grew 6.4% to $22.1 million, driven by Oncology and Wound Care, while Device Solutions revenue fell 16.9% to $11.6 million, mainly from lower biomedical services and equipment sales.

• Wound Care revenue more than doubled year-over-year, now representing 6% of total revenue, with growth driven by new compression device partnerships.

• Device Solutions gross margin improved by 7.2% due to contract restructuring, despite revenue declines.

• Gross profit rose $515,000 (3%) to $19.7 million, with gross margin up 3.2% to just over 58%.

• SG&A expenses decreased by $0.5 million, aided by the absence of prior year CEO severance and lower bonuses.

Outlook and guidance

• Full-year 2026 net revenue guidance reaffirmed, with pro-forma growth expected between 6% and 8% and adjusted EBITDA margin anticipated in the low to mid 20% range.

• ERP-related costs will continue but are expected to taper down by year-end, with cost savings anticipated to materialize in 2027.

• Oncology RCM migration to Apollo platform remains on track for completion by year-end.

• Liquidity remains strong with $2.1 million in cash and $55 million available on the revolving credit facility.